Cite
HARVARD Citation
Chelariu-Raicu, A. et al. (2020). Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. International journal of gynecological cancer. 30 (11), p. . [Online].